Optimal adoption of biomarker testing is necessary for cancer patients to reap the benefits of biomarker-based targeted therapies, yet testing rates vary greatly across biomarkers and tumor types. Variability in Oncology Biomarker Testing Rates. Within just a few months after the launch of the first BRAF-targeted treatment for melanoma, nearly ....